Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04498455 · ClinicalTrials.gov registry record · Phase 4
Study of a Prebiotic Supplement to Mitigate Excessive Weight Gain Among Physicians in Residency
A Phase 4 study of Metabolic Syndrome and Weight Gain Trajectory, sponsored by Baylor University.
- Completed
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT04498455: Completed Phase 4 study of Metabolic Syndrome and Weight Gain Trajectory, sponsored by Baylor University.
NCT04498455 is a Phase 4 study of Metabolic Syndrome and Weight Gain Trajectory that has completed, run by Baylor University. The registered enrollment target is 11 participants, below the 1,205-participant average among 102 other Metabolic Syndrome trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04498455, a Phase 4 study of Metabolic Syndrome and Weight Gain Trajectory, has completed, sponsored by Baylor University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
A randomized placebo controlled trial to determine if increased dietary fiber will prevent weight gain, inhibit adiposity and reduce perceived stress levels in residents at the Waco Family Health Center as the result of changes in distal gut microbiota composition and function.
Primary Outcome
The investigators will use the following procedure to assess the effect of Prebiotin (OEI) on changes in body weight: there will be two test days: a) baseline (Day 0), prior to randomization to OEI or placebo; and b) week 12, following the 11 week course of OEI/placebo treatment. The investigators will use OEI for the inulin challenge. Change in body weight will be quantified by bio electrical impedance.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Prebiotin
Study Locations (1)
Texas
- Baylor University - Waco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-09-30 |
| Est. Completion | 2019-02-15 |
| Phase | Phase 4 |
What the finished NCT04498455 record still lists
NCT04498455 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 1,205-participant average among 102 other Metabolic Syndrome trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Metabolic Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Prebiotin is the first listed.
NCT04498455 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04498455 about?
NCT04498455 is a clinical study titled "Study of a Prebiotic Supplement to Mitigate Excessive Weight Gain Among Physicians in Residency". A randomized placebo controlled trial to determine if increased dietary fiber will prevent weight gain, inhibit adiposity and reduce perceived stress levels in residents at the Waco Family Health Center as the result of changes in distal gut microbiota composition and function.
What is the current status of trial NCT04498455?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2018-09-30. Estimated completion is 2019-02-15.
What conditions does trial NCT04498455 study?
This clinical trial studies the following conditions: Metabolic Syndrome, Weight Gain Trajectory.
What interventions are being tested in trial NCT04498455?
The interventions under investigation include: Prebiotin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04498455?
This trial is sponsored by Baylor University, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04498455 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metabolic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04498455's enrollment target sits among peer trials
11 101st of 102 higher than 2 of 102 other Metabolic Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metabolic Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact GLP-1 Agonists Following Bariatric
RECRUITING · Phase 4
-
Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome
RECRUITING · Phase 4
-
A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin
COMPLETED · Phase 4
-
Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism
COMPLETED · Phase 4
-
Effect of Rosiglitazone in Nondiabetic Patients With the Metabolic Syndrome
COMPLETED · Phase 4
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI